
Sign up to save your podcasts
Or


Elevated CAC in highly active men doesn't raise risk of death, Life's Simple 7 scores can be used to modify PAD risk, medical guidance often leads atrial fibrillation patients to needlessly seek emergency care, and thinking of pregnancy as a stress test can help predict women's future cardiovascular risk.
This week in cardiology news, revised atrial fibrillation guidelines revamp anticoagulation, the SPRINT MIND results showing that tight BP control staves off mild cognitive impairment are published, the FDA discovers that nitrosamine-contaminated ARBs have been on the market for years, and subclinical hypothyroidism boosts the immediate risk of heart failure.
This week, the FDA weighs in on concerning reports about paclitaxel-coated stents, and it approves a device to treat patent ductus arteriosus in infants weighing as little as 2 pounds. Also, a treat-to-target approach for CVD risk factors decreased atherosclerosis in rheumatoid arthritis patients, and ezetimibe was effective for primary prevention in elderly patients.
This week in MDedge Cardiocast: too little sleep, too much sleep, and fragmented sleep are all linked to atherosclerosis; dabigatran matches aspirin for second stroke prevention; HDL particle subfractions may be prognostic in heart failure; and a novel drug safely reduced LDL cholesterol in statin-intolerant patients.
This week from MDedge Cardiology, a biodegradable polymer shows no long-term benefit in heart stents, appropriate use criteria for imaging in nonvalvular heart disease are released, ACOG updates guidance on hypertension in pregnancy, and more losartan lots are recalled.
This week from MDedge Cardiology, a biodegradable polymer shows no long-term benefit in heart stents, appropriate use criteria for imaging in nonvalvular heart disease are released, ACOG updates guidance on hypertension in pregnancy, and more losartan lots are recalled.
This week in Cardiocast, the Hospital Readmissions Reduction Program may be doing more harm than good, ticagrelor holds no edge over aspirin in CABG patients, weight-loss apps lack evidence, and the Surgeon General sends out an alarm.
This week, the barbershop may become a key battleground in the fight against hypertension, the American Diabetes Association upgrades newer antihyperglycemics, refreshed appropriate use criteria for peripheral artery disease are released, and body mass index as a measure of cardiometabolic risk gets a boost.
This week, the American Heart Association says that statins' benefits far outweigh the risks, a smartphone app is nearly as good as an ECG at diagnosing STEMI, stroke thrombolysis appears safe in patients prone to GI bleeding, and a new strategy for pausing DOAC therapy works in A-fib patients.
This week, apixaban edges out other DOACs for octogenarians, methotrexate fails to cut cardiovascular events in a large trial, withdrawing heart failure medications after recovery leads to relapse, and showing patients their own atherosclerosis may reduce their cardiovascular event risk.
From the publisher's feed